|
[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Khorana, A.A., Mangu, P.B., Berlin, J., et al. (2016) Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 34, 2541-2556. [Google Scholar] [CrossRef]
|
|
[4]
|
Ohaegbulam, K.C., Assal, A., Lazar-Molnar, E., et al. (2015) Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway. Trends in Molecular Medicine, 21, 24-33. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Wei, S.C., Duffy, C.R. and Allison, J.P. (2018) Fun-damental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 8, 1069-1086. [Google Scholar] [CrossRef]
|
|
[6]
|
Kasakovski, D., Skrygan, M., Gambichler, T., et al. (2021) Advances in Targeting Cutaneous Melanoma. Cancers (Basel), 13, 2090. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Majidpoor, J. and Mortezaee, K. (2021) The Efficacy of PD-1/PD-L1 Blockade in Cold Cancers and Future Perspectives. Clinical Immunology, 226, Article ID: 108707. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Patnaik, A., Kang, S.P., Rasco, D., et al. (2015) Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 21, 4286-4293. [Google Scholar] [CrossRef]
|
|
[9]
|
Weiss, G.J., Blaydorn, L., Beck, J., et al. (2018) Phase Ib/II Study of Gemcitabine, Nab-Paclitaxel, and Pembrolizumab in Metastatic Pancreatic Adenocarcinoma. Investigational New Drugs, 36, 96-102. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Cancer Genome Atlas, N. (2012) Comprehensive Molecular Characterization of Human Colon and Rectal Cancer. Nature, 487, 330-337. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Hu, Z.I., Shia, J., Stadler, Z.K., et al. (2018) Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 24, 1326-1336. [Google Scholar] [CrossRef]
|